Diagnostics company SphingoTec GmbH reports novel applications of bio-ADM® (bio-active adrenomedullin), the very first biomarker capable to diagnose the onset of septic shock, allowing physicians…
German diagnostics company SphingoTec GmbH (Hennigsdorf) announced that leaders in critical care nephrology have confirmed clinical utility of the company’s glomerular filtration biomarker…
bio-ADM, the very first blood biomarker capable to diagnose when blood vessels become leaky (endothelial dysfunction), is set to make a rapid carrier at intensive care units (ICUs) and emergency…
German diagnostics company SphingoTec GmbH has closed a €20m growth equity financing round led by international healthcare specialist investors HBM and Wellington Partners.
German diagnostics company SphingoTec GmbH (Hennigsdorf) and Nexus Dx (San Diego) have combined their technology platforms to market sphingotec’s CE-marked acute biomarkers penKid® and bio-ADM® on…
Disorders caused by a leaky vasculature are more common than most people think. Despite ICU treatment, one third of the 27 million patients globally that suffer from sepsis, and up to 20% of the more…
sphingotest® bio-ADM® Assay can help reduce re-admissions and death by measuring residual congestion. Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, and SphingoTec GmbH…
Researchers from other institutions can request to have their studies performed using these biomarkers. SphingoTec GmbH , a biotechnology company that develops biomarkers for the detection and…
scientific paper shows proenkephalin as the new biomarker for the assessment of kidney function as a more accurate marker to timely detect impaired kidney function when compared with conventional…
German diagnostic company SphingoTec GmbH (Hennigsdorf) and Chinese Company Shuwen Biotech Co. Ltd (Deqing) have signed an agreement to market Sphingotec’s biomarkers portfolio in China.
